Vitae Pharmaceuticals Inc. is getting $42 million up front in an early stage deal with Boehringer Ingelheim GmbH aimed at the much-sought-after - though difficult - space of disease-modifying drugs against Alzheimer's disease. (BioWorld Today) Read More
